Author(s):
Kajal, Richa Kumari, Rajesh, Rahul, Rishab, Arvind Sharma
Email(s):
kajalmandyal22@gmail.com
DOI:
10.52711/2231-5659.2024.00049 
Address:
Kajal1*, Richa Kumari2, Rajesh2, Rahul2, Rishab2, Arvind Sharma3
1Assistant Professor, School of Pharmacy, Abhilashi University, Mandi, Himachal Pradesh, India.
2Research Scholar, School of Pharmacy, Abhilashi University, Mandi, Himachal Pradesh, India.
3Dean and Professor, School of pharmacy, Abhilashi University Mandi, Himachal Pradesh, India.
*Corresponding Author
Published In:
Volume - 14,
Issue - 3,
Year - 2024
ABSTRACT:
Neurodegenerative disorders are primarily characterized by neuron loss. The most common neurodegenerative disorders include Alzheimer’s and Parkinson’s disease. Although there are several medicines currently approved for managing neurodegenerative disorders, a large majority of them only help with associated symptoms. This lack of pathogenesis-targeting therapies is primarily due to the restrictive effects of the blood–brain barrier (BBB), which keeps close to 99% of all “foreign substances” out of the brain. Since their discovery, nanoparticles have been successfully used for targeted delivery into many organs, including the brain.
Cite this article:
Kajal, Richa Kumari, Rajesh, Rahul, Rishab, Arvind Sharma. A Review on New Drug Development for the Treatment of Neurodegenerative Disease. Asian Journal of Research in Pharmaceutical Sciences. 2024; 14(3):304-2. doi: 10.52711/2231-5659.2024.00049
Cite(Electronic):
Kajal, Richa Kumari, Rajesh, Rahul, Rishab, Arvind Sharma. A Review on New Drug Development for the Treatment of Neurodegenerative Disease. Asian Journal of Research in Pharmaceutical Sciences. 2024; 14(3):304-2. doi: 10.52711/2231-5659.2024.00049 Available on: https://ajpsonline.com/AbstractView.aspx?PID=2024-14-3-18
REFERENCES:
1. People all over the world are suffering from neurodegenerative diseases, which are illnesses that lead to cell death in the brain. Some neurodegenerative diseases, like Parkinson’s Disease and Huntington’s Disease, affect the basal ganglia and lead to movement difficulties. Other diseases cause more widespread cell death and lead to memory loss, which is seen in Alzheimer’s Disease and Lewy body d
2. Cular pathological classification of neurodegenerative diseases: Turning towards precision medicine. Int J Mol Sic., 2016; 17: 189.
3. Przedborski S, Vila M, Jackson LV. Neurodegenerative: what is It and where are we? The Journal of Clinical Investigation. 2003; 111(1): 3-10.
4. Peter O donnell. Neurodegenerative Disorders. UT southwestern Medical center. 2022
5. Obrocki P, Khatun A, Ness D, Konstantin S, Jorg H, et al. Perspectives in fluid bio-markers in Neurodegenerative from the 2019 bio-markers in neurodegenerative diseases course-a joint PhD student Course at university college London and university of gothenburg. Alz Res Therapy. 2020; 12(20).
6. Allison DJ and Ditor DS: The common inflammatory etiology of depression and cognitive impairment: A therapeutic target. J. Neuroinflammation. 2014; 11: 151.
7. De Leeuw FE, de Groot JC, Oudkerk M, Witteman JC, Hofman A, van Gijn J and Breteler MM: Hypertension and Cerebral white matter lesions in a prospective cohort study. Brain. 2002; 125: 765-772.
8. Schiffrin EL: Inflammation, immunity and development of Essential hypertension. J. Hypertens. 2014; 32: 228‑229.
9. Shimizu M, Ishikawa J, Yano Y, Hoshide S, Shimada K and kario k. relationship between the morning blood pressure Surge and low‑grade inflammation on silent cerebral infarct and Clinical stroke events. Atherosclerosis. 2011; 219: 316-321.
10. Tousoulis D, Kampoli AM, Papageorgiou N, Androulakis E, Antoniades C, Toutouzas K and Stefanadis C: Pathophysiology Of atherosclerosis: The role of inflammation. Curr Pharm Des. 2011; 17: 4089‑4110.
11. Di Napoli M, Godoy DA, Campi V, Masotti L, Smith CJ, Parry Jones AR, Hopkins SJ, Slevin M, Papa F, Mogoanta L, EtAl: C-reactive protein in intracerebral hemorrhage: Time course, Tissue localization, and prognosis. Neurology. 2012; 79: 690-699.
12. Di Napoli M, Parry‑Jones AR, Smith CJ, Hopkins SJ, SlevinM, Masotti L, Campi V, Singh P, Papa F, Popa-Wagner A, EtAl:C‑rotein predicts hematoma growth in intracerebral Hemorrhage. Stroke. 2014; 45: 59-65.
13. Rizzo M, Corrado E, Coppola G, Muratori I, Mezzani A, Novo G and Novo S: The predictive role of C‑reactive protein in patients with hypertension and subclinical atherosclerosis. Intern Med J. 2009; 39: 539-545.
14. Rizzo M, Corrado E, Coppola G, Muratori I, Novo G and Novo S: Markers of inflammation are strong predictors of Subclinical and clinical atherosclerosis in women with hyper-Tension. Coron Artery Dis. 2009; 20: 15-20.
15. Goossens GH: The role of adipose tissue dysfunction in the Pathogenesis of obesity -related insulin resistance. Physiol Behav. 2008; 94: 206‑218.
16. Goossens GH, Bizzarri A, Venteclef N, Essers Y, Cleutjens JP, Konings E, Jocken JW, Čajlaković M, Ribitsch V, Clément K, Et Al: Increased adipose tissue oxygen tension in Obese compared with lean men is accompanied by insulin Resistance, impaired adipose tissue capillarization, and inflam-Mation. Circulation. 2011; 124: 67-76.
17. Howcroft TK, Campisi J, Louis GB, Smith MT, Wise B, Wyss‑Coray T, Augustine AD, McElhaney JE, Kohanski R and Sierra F: The role of inflammation in age‑related disease. Aging (Albany NY). 2013; 5: 84‑93.
18. Olefsky JM and Glass CK: Macrophages, inflammation, and Insulin resistance. Annu Rev Physiol. 2010; 72: 219-246.
19. Bruunsgaard H, Pedersen M and Pedersen BK: Aging and Proinflammatory cytokines. CurrOpinHematol. 2001; 8: 131‑136.
20. Fagiolo U, Cossarizza A, Santacaterina S, Ortolani C, Monti D, Paganelli R and Franceschi C: Increased cytokine production by peripheral blood mononuclear cells from healthy elderly People. Ann N Y AcadSci. 1992; 663: 490‑493.
21. Fagiolo U, Amadori A, Cozzi E, Bendo R, Lama M, Douglas A and Palù G: Humoral and cellular immune response to Influenza virus vaccination in aged humans. Aging (Milano). 1993; 5: 451‑458.
22. Fagiolo U, Cossarizza A, Scala E, Fanales-Belasio E, Ortolani C, Cozzi E, Monti D, Franceschi C and Paganelli R: Increased cytokine production in mononuclear cells of healthy Elderly people. Eur J Immunol. 1993; 23: 2375‑2378.
23. Johnson FA, Dawson AJ and Meyer RL: Activity‑dependent Refinement in the goldfish retinotectal system is mediated by The dynamic regulation of processes withdrawal: An in vivo Imaging study. J Comp Neurol. 1999; 406: 548‑562.
24. Capuron L, Su S, Miller AH, Bremner JD, Goldberg J, Vogt GJ, Maisano C, Jones L, Murrah NV and Vaccarino V: Depressive Symptoms and metabolic syndrome: Is inflammation the Underlying link? Biol Psychiatry. 2008; 64: 896‑900.
25. Ouchi N, Parker JL, Lugus JJ and Walsh K: Adipokines in Inflammation and metabolic disease. Nat Rev Immunol. 2011; 11: 85‑97.
26. Capuron L, Poitou C, Machaux-Tholliez D, Frochot V, Bouillot JL, Basdevant A, Layé S and Clément K: Relationship Between adiposity, emotional status and eating behaviour in Obese women: Role of inflammation. Psychol Med. 2011; 41: 1517‑1528.
27. Cancello R, Henegar C, Viguerie N, Taleb S, Poitou C, RouaultC, Coupaye M, Pelloux V, Hugol D, Bouillot JL, Et al: Reduction Of macrophage infiltration and chemoattractant gene expression Changes in white adipose tissue of morbidly obese subjects after Surgery‑induced weight loss. Diabetes. 2005; 54: 2277‑2286.
28. McCrimmon RJ, Ryan CM and Frier BM: Diabetes and cognitive Dysfunction. Lancet. 2012; 379: 2291-2299.
29. McIntyre RS, Soczynska JK, Konarski JZ, Woldeyohannes HO, Law CW, Miranda A, Fulgosi D and Kennedy SH: Should Depressive syndromes be reclassified as ‘metabolic syndrome TypeII’? Ann Clin Psychiatry. 2007; 19: 257‑264.
30. Wolkowitz OM, Epel ES, Reus VI and Mellon SH: Depression Gets old fast: Do stress and depression accelerate cell aging? Depress Anxiety. 2010; 27: 327‑338.
31. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, Et al: Acute and longer-Term outcomes in Depressed outpatients requiring one or several treatment steps: A STAR*D report. Am J Psychiatry. 2006; 163: 1905-1917.
32. Baune BT, Smith E, Reppermund S, Air T, Samaras K, LuxO, Brodaty H, Sachdev P and Trollor JN: Inflammatory bio-markers predict depressive, but not anxiety symptoms during Aging: The prospective Sydney Memory and Aging Study. Psychoneuroendocrinology. 2012; 37: 1521-1530.
33. Najjar S, Pearlman DM, Devinsky O, Najjar A and Zagzag D: Neurovascular unit dysfunction with blood‑brain barrier hyper-Permeability contributes to major depressive disorder: A review of clinical and experimental evidence. J Neuroinflammation. 2013; 10: 142.
34. Zunszain PA, Hepgul N and Pariante CM: Inflammation and Depression. Curr Top Behav Neurosci. 2013; 14: 135-151.
35. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR and Walters EE: Lifetime prevalence and age-ofonset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005; 62: 593‑602.
36. Papakostas GI, Shelton RC, Kinrys G, Henry ME, Bakow BR, Lipkin SH, Pi B, Thurmond L and Bilello JA: Assessment Of a multi-Assay, serum-Based biological diagnostic test for Major depressive disorder: A pilot and replication study. Mol Psychiatry. 2013; 18: 332‑339.
37. Rivest S: Regulation of innate immune responses in the brain. Nat Rev Immunol. 2009; 9: 429-439.
38. Yang WX, Terasaki T, Shiroki K, Ohka S, Aoki J, Tanabe S, Nomura T, Terada E, Sugiyama Y and Nomoto A: Efficient Delivery of circulating poliovirus to the central nervous system Independently of poliovirus receptor. Virology. 1997; 229: 421‑428.
39. Aronsson F, Robertson B, Ljunggren HG and Kristensson K: Invasion and persistence of the neuroadapted influenza virus A/WSN/33 in the mouse olfactory system. Viral Immunol. 2003; 16: 415-423.
40. Schnell G, Joseph S, Spudich S, Price RW and Swanstrom R: HIV‑1 replication in the central nervous system occurs in two Distinct cell types. PLoSPathog.7: e1002286, 2011.
41. Chen L, Liu J, Xu C, Keblesh J, Zang W and Xiong H: HIV‑1gp120 induces neuronal apoptosis through enhancement of 4‑aminopyridine‑senstive outward K+ currents. PLoS One. 6: E25994, 2011.
42. Chang JR, Mukerjee R, Bagashev A, Del Valle L, Chabrashvili T, Hawkins BJ, He JJ and Sawaya BE: HIV‑1 Tat protein promotes Neuronal dysfunction through disruption of microRNAs. J Biol Chem 288: 8564, 2013.
43. Brew BJ, Crowe SM, Landay A, Cysique LA and Guillemin G: Neurodegenerative and ageing in the HAART era. J. Neuroimmune Pharmacol.2009; 4: 163-174.
44. Alzheimer Europe.Dementia in Europe Yearbook 2019: estimating the prevalence of Dementia in Europe. 2020. https:// www.alzheimereurope.org/content/download/195515/1457520/File/FINAL%2005707%20Alzheimer%20Europe%20yearbook%202019.pdf (accessed Jan 24, 2021)
45. Scheltens P, Blennow K, Breteler MM, et al. Alzheimer’s disease. Lancet. 2016; 388: 505–17. [PubMed: 26921134]
46. Food and Drug Administration. An interim report from the FDA. N Engl J Med. 1991; 324: 349-52.
47. Leber P. Draft guidelines for the clinical evaluation of antidementia Drugs. Washington, D.C.: Food and Drug Administration. 1990. (FDA Publication no. F91-19331.)
48. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s Disease. Am J Psychiatry. 1984; 141: 1356-64.
49. Reisberg B, Schneider L, Doody R, et al. Clinical global measures of Dementia: position paper from the International Work Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord. 1997; 11: Suppl 3: S8-S18.
50. Knopman DS, Knapp MJ, Gracon SI, Davis CS. The Clinician Interview-Based Impression (CIBI): a clinician’s global change rating scale in Alzheimer’s disease. Neurology. 1994; 44: 2315-21.
51. Folstein MF, Folstein SE, McHugh PR. Mini–Mental State: a practical Method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12: 189-98.
52. Stern RG, Mohs RC, Davidson M, et al. A longitudinal study of Alzheimer’s disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry. 1994; 151: 390-6.
53. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change: the Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997; 11: Suppl 2: S22-S32.
54. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34: 939-44. Price DL, Thinakaran G, Borchelt DR, et al. Neuropathology of Alzheimer’s disease and animal models. In: Markesbery WR, ed. Neuropathology of dementing disorders. London: Arnold. 1998: 121-41
55. 11. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry. 1984; 141: 1356-64.
56. 12. Reisberg B, Schneider L, Doody R, et al. Clinical global measures of dementia: position paper from the International Work Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord 1997; 11: Suppl 3: S8-S18.
57. 13. Knopman DS, Knapp MJ, Gracon SI, Davis CS. The Clinician Interview-Based Impression (CIBI): a clinician’s global change rating scale in Alzheimer’s disease. Neurology. 1994; 44: 2315-21.
58. 14. Folstein MF, Folstein SE, McHugh PR. Mini–Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12: 189-98.
59. Atri A, Frolich L, Ballard C, et al. Effect of idalopirdine as adjunct to cholinesterase inhibitors on change in cognition in patients with Alzheimer disease: three randomized clinical trials. JAMA. 2018; 319: 130–42. [PubMed: 29318278]
60. Cummings J, Ballard C, Tariot P, et al. Pimavanserin: potential treatment for dementia-related psychosis. J Prev Alzheimers Dis. 2018; 5: 253–58. [PubMed: 30298184]
61. Halpern R, Seare J, Tong J, Hartry A, Olaoye A, Aigbogun MS. Using electronic health records to estimate the prevalence of agitation in Alzheimer disease/dementia. Int J Geriatr Psychiatry, 2019; 34: 420–31. [PubMed: 30430642]
62. Liu CS, Ruthirakuhan M, Chau SA, Herrmann N, Carvalho AF, Lanctot KL. Pharmacological management of agitation and aggression in Alzheimer’s disease: a review of current and novel treatments. Curr Alzheimer Res. 2016; 13: 1134–44. [PubMed: 27137221]
63. K, Prichard JR, Pusalavidyasagar S. An update on dual orexin receptor antagonists and their potential role in insomnia therapeutics. J Clin Sleep Med. 2018; 14: 1399–408. [PubMed: 30092886]
64. Cummings JC, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer’s disease drug development pipeline: 2020. Alzheimer Dement. 2020; 6: e12050.
65. Sevigny J, Chiao P, Bussiere T, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. 2016; 537: 50–56. [PubMed: 27582220]
66. Van Dyck CH. Anti-amyloid-β monoclonal antibodies for Alzheimer’s disease: pitfalls and promise. Bio Psychiatry. 2017; 83: 311–19. [PubMed: 28967385]
67. Lilly. News release: Lilly’s donanemab slows clinical decline of Alzheimer’s disease in positive phase 2 trial. Jan 11, 2021. https://investor.lilly.com/news-releases/news-release details/lillysdonanemab-slows-clinical-declinealzheimersdisease#:~:text=11%2C%202021%20%2FPRNewswire%2F%20%2D%2D,results%20from%20Eli%20Lilly%20 and (accessed Jan 24, 2021)
68. Egan MF, Kost J, Voss T, et al. Randomized trial of verubecestat for prodromal Alzheimer’s disease. N Engl J Med. 2019; 380: 1408–20. [PubMed: 30970186]
69. Parkinson J. An Essay on the Shaking Palsy. London: Sherwood, Neely, and Jones; 1817: 1–16.
70. Twelves D, Perkins KS, Counsell C. Systematic review of incidence Studies of Parkinson’s disease. Mov Disord. 2003; 18: 19–31.
71. National Institute for Health and Care Excellence (NICE). Parkinson’s disease: diagnosis and management in primary and Secondary care. NICE clinical guidelines 35. June 2006. Available at: http://www.nice.org.uk/guidance/cg35/resources/ guidanceparkinsons-disease-pdf. Accessed April 28, 2015.
72. Schrag A, Horsfall L, Walters K, et al. Prediagnostic presentations of Parkinson’s disease in primary care: a case-control study. Lancet Neurol. 2015; 1: 57–64.
73. Parkinson’s Disease Foundation. Statistics on Parkinson’s. Available at: www.pdf.org.en/parkinson_statistics. Accessed June 19, 2014.
74. Driver JA, Logroscino G, Gaziano JM, et al. Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology. 2009; 72: 32–38.
75. De Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurol. 2006; 5: 525–535
76. Chen JJ, Swope DM. Parkinson’s disease. In: DiPiro JT, Talbert RL, Yee GC, et al., eds. Pharmacotherapy: A Pathophysiologic Approach, 9th ed. New York, New York: McGraw-Hill. 2014.
77. Lim SY, Fox SH, Lang AE. Overview of the extranigral aspects of Parkinson disease. Arch Neurol. 2009; 66: 167–172.
78. Wolters EC, Braak H. Parkinson’s disease: premotor clinicopathological correlations. J Neural Transm Suppl. 2006; 70: 309–319.
79. Postuma RB, Aarsland D, Barone P, et al. Identifying prodromal Parkinson’s disease: pre-motor disorders in Parkinson’s disease. Mov Disord. 2012; 27: 617–626.
80. Siderowf A, Lang AE. Premotor Parkinson’s disease: concepts and definitions. Mov Disord. 2012; 15(27): 608–616
81. Willis GL, Moore C, Armstrong SM. Breaking away from dopamine deficiency: an essential new direction for Parkinson’s disease. Rev Neurosci. 2012; 23: 403–428.
82. Jellinger KA. Neuropathology of sporadic Parkinson’s disease: evaluation and changes of concepts. Mov Disord. 2012; 27: 8–30.
83. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003; 24: 197–211.
84. Braak H, Braak E. Pathoanatomy of Parkinson’s disease. J Neurol. 2000; 247(suppl 2): 3–10.
85. Kovari E, Horvath J, Bouras C. Neuropathology of Lewy body disorders. Brain Res Bull. 2009; 80: 203–210.
86. Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011; 63: 182–217.
87. Galvan A, Wichmann T. GABAergic circuits in the basal ganglia and movement disorders. Prog Brain Res. 2007; 160: 287–312.
88. Chu J, Wagle-Shukla A, Gunraj C, et al. Impaired presynaptic inhibition in the motor cortex in Parkinson disease. Neurology. 2009; 72: 842–849.
89. Caviness JN. Pathophysiology of Parkinson’s disease behavior: a view from the network. Parkinsonism Relat Disord. 2014; 20(suppl 1): S39–S43.
90. Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008; 79: 368–76.
91. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s Disease. Mov Disord. 2015; 30: 1591–601.
92. 15 Marek K, Chowdhury S, Siderowf A, et al. The Parkinson’s progression markers Initiative (PPMI) – establishing a PD biomarker cohort. Ann Clin Transl Neurol. 2018; 5: 1460–77.
93. Giguère N, Burke Nanni S, Trudeau LE. On cell loss and selective vulnerability of Neuronal populations in Parkinson’s disease. Front Neurol. 2018; 19: 455.
94. Espay AJ, Vizcarra JA, Marsili L, et al. Revisiting protein aggregation as pathogenic in Sporadic Parkinson and Alzheimer diseases. Neurology. 2019; 92: 329–37.
95. Chaudhuri KR, Sauerbier A, disease P. Unravelling the nonmotor mysteries of Parkinson disease. Nat Rev Neurol. 2016; 12: 10–11.
96. Aarsland D, Creese B, Politis M, et al. Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017; 13: 217–31.
97. Hughes KC, Gao X, Baker JM, et al. Non-motor features of Parkinson’s disease In a nested case–control study of US men. J Neurol Neurosurg Psychiatry. 2018; 89: 1288–95.
98. Kalia LV, Brotchie JM, Fox SH. Novel nondopaminergic targets for motor features of Parkinson’s disease: review of recent trials. Mov Disord. 2013; 28: 131–44.
99. Mantri S, Morley JF, Siderowf AD. The importance of preclinical diagnostics in Parkinson disease. Parkinsonism Relat Disord. 2019; 64: 20–8.
100. Postuma RB, Aarsland D, Barone P, et al. Identifying prodromal Parkinson’s disease: Pre-motor disorders in Parkinson’s disease. Mov Disord. 2012; 27: 617–26.
101. Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nat Rev Dis Primers. 2017; 3: 1701.
102. Heinzel S, Berg D, Gasser T, et al. Update of the MDS research criteria for prodromal Parkinson’s disease. Mov Disord. 2019; 34: 1464–70
103. The Parkinson Study Group. Effects of tocopherol and deprenyl on The progression of disability in early Parkinson’s disease. N Engl J Med. 1993; 328: 176-83.
104. Idem. Impact of deprenyl and tocopherol treatment on Parkinson’s Disease in DATATOP subjects not requiring levodopa. Ann Neurol. 1996; 39: 29-36.
105. Idem. Impact of deprenyl and tocopherol treatment on Parkinson’s Disease in DATATOP patients requiring levodopa. Ann Neurol. 1996; 39: 37-45.
106. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and Levodopa on the progression of Parkinson’s disease. Ann Neurol. 1995; 38: 771-7.
107. Mytilineou C, Radcliffe PM, Olanow CW. L-(-)-desmethylselegiline, A metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro. J Neurochem. 1997; 68: 434-6.
108. Lees AJ. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson’s disease. BMJ. 1995; 311: 1602-7.
109. Olanow CW, Fahn S, Langston JW, Godbold J. Selegiline and mortality in Parkinson’s disease. Ann Neurol. 1996; 40: 841-5.
110. Mäki-Ikola O, Kilkku O, Heinonen E. Effect of adding selegiline to Levodopa in early, mild Parkinson’s disease: other studies have not shown Increased mortality. BMJ. 1996; 312: 702.